These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17704517

  • 1. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
    Hope R, Parsons T, Mushtaq S, James D, Livermore DM.
    J Antimicrob Chemother; 2007 Oct; 60(4):770-4. PubMed ID: 17704517
    [Abstract] [Full Text] [Related]

  • 2. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.
    Casal M, Rodríguez F, Johnson B, Garduno E, Tubau F, de Lejarazu RO, Tenorio A, Giménez MJ, Bartolomé R, Garcia-Rey C, Aguilar L, García-Escribano N.
    J Antimicrob Chemother; 2009 Jul; 64(1):69-72. PubMed ID: 19451133
    [Abstract] [Full Text] [Related]

  • 3. Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK.
    Hope R, Mushtaq S, James D, Pllana T, Warner M, Livermore DM, Tigecycline Susceptibility Testing Group.
    J Antimicrob Chemother; 2010 Dec; 65(12):2602-9. PubMed ID: 20930043
    [Abstract] [Full Text] [Related]

  • 4. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
    Tubau F, Liñares J, Rodríguez MD, Cercenado E, Aldea MJ, González-Romo F, Torroba L, Berdonces P, Plazas J, Aguilar L, Delgado A, García-Escribano N, Study Group.
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, Hellenic Tigecycline Study Group.
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [Abstract] [Full Text] [Related]

  • 6. Validation and reproducibility assessment of tigecycline MIC determinations by Etest.
    Bolmström A, Karlsson A, Engelhardt A, Ho P, Petersen PJ, Bradford PA, Jones CH.
    J Clin Microbiol; 2007 Aug; 45(8):2474-9. PubMed ID: 17522277
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H, Dowzicky MJ.
    Chemotherapy; 2009 Aug; 55(4):241-52. PubMed ID: 19468222
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C, Rodríguez-Avial I, Gómez M, Culebras E, López F, Alvarez J, Picazo JJ, Spanish Tigecycline Group.
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
    [Abstract] [Full Text] [Related]

  • 11. BSAC standardized disc susceptibility testing method (version 7).
    Andrews JM, BSAC Working Party on Susceptibility Testing.
    J Antimicrob Chemother; 2008 Aug; 62(2):256-78. PubMed ID: 18474513
    [Abstract] [Full Text] [Related]

  • 12. Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation.
    Kronvall G, Karlsson I, Walder M, Sörberg M, Nilsson LE.
    J Antimicrob Chemother; 2006 Mar; 57(3):498-505. PubMed ID: 16410264
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.
    Hope R, Warner M, Mushtaq S, Ward ME, Parsons T, Livermore DM.
    J Antimicrob Chemother; 2005 Dec; 56(6):1042-6. PubMed ID: 16286361
    [Abstract] [Full Text] [Related]

  • 15. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods.
    Liao CH, Kung HC, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Cheng YJ, Lin HC, Shi ZY, Wang LS, Chuang YC, Tsao SM, Lu CT, Liu JW, Huang CH, Hsueh PR.
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S192-6. PubMed ID: 19013354
    [Abstract] [Full Text] [Related]

  • 16. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S, Marchese A, Debbia EA.
    Chemotherapy; 2008 Nov; 54(1):43-9. PubMed ID: 18073470
    [Abstract] [Full Text] [Related]

  • 17. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
    Gales AC, Sader HS, Fritsche TR.
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):421-7. PubMed ID: 18068934
    [Abstract] [Full Text] [Related]

  • 18. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.
    Vouillamoz J, Moreillon P, Giddey M, Entenza JM.
    J Antimicrob Chemother; 2008 Feb; 61(2):371-4. PubMed ID: 18033780
    [Abstract] [Full Text] [Related]

  • 19. Comparison of three standardized disc susceptibility testing methods for colistin.
    Tan TY, Ng LS.
    J Antimicrob Chemother; 2006 Oct; 58(4):864-7. PubMed ID: 16905528
    [Abstract] [Full Text] [Related]

  • 20. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.